Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

<ul>
<li>We analyse the changes of A/H premium on 140 stocks over the last week.</li>
<li>The decline in A-H premium were led by health care and consumer staples, which was offset by the increase in consumer discretionary. </li>
<li>We highlight A-H premium changes in Zhejiang Shibao, PICC, CRRC, Shandong Xinhua, and Shenwan Hongyuan.</li>
</ul>


We analyse the changes of A/H premium on 140 stocks over the last week.
The decline in A-H premium were led by health care and consumer staples, which was offset by the increase in consumer discretionary. 
We highlight A-H premium changes in Zhejiang Shibao, PICC, CRRC, Shandong Xinhua, and Shenwan Hongyuan.


A-H Premium Weekly: Zhejiang Shibao, PICC, CRRC

<ul>
<li>We analyse the changes of A/H premium on 140 stocks over the last week.</li>
<li>Weekly A-H premium change of -0.7ppt was led by the consumer staple, consumer discretionary, and utilities sector.</li>
<li>We highlight stocks including Remegen, CNOOC, COSCO Shipping, Cansino, Nanjing Panda, Shenzhen Hepalink, SH Fudan, SH Haohai, China Telecom, and Sinotrans.</li>
</ul>


We analyse the changes of A/H premium on 140 stocks over the last week.
Weekly A-H premium change of -0.7ppt was led by the consumer staple, consumer discretionary, and utilities sector.
We highlight stocks including Remegen, CNOOC, COSCO Shipping, Cansino, Nanjing Panda, Shenzhen Hepalink, SH Fudan, SH Haohai, China Telecom, and Sinotrans.


A-H Premium Weekly: Remegen, CNOOC, COSCO Shipping

<ul>
<li>We analyse the changes of A/H premium on 138 stocks over the last week.</li>
<li>Consumer staple, consumer discretionary and heathcare led the 3.0ppt weekly A-H premium decline. </li>
<li>We highlight names including Shenzhen HepaLink, Shandong Xinhua Pharm, and Shanghai Haohai Biological Technology.</li>
</ul>


We analyse the changes of A/H premium on 138 stocks over the last week.
Consumer staple, consumer discretionary and heathcare led the 3.0ppt weekly A-H premium decline. 
We highlight names including Shenzhen HepaLink, Shandong Xinhua Pharm, and Shanghai Haohai Biological Technology.


A-H Premium Weekly: Healthcare Led Premium Decline

<ul>
<li>We analyse the changes of A/H premium on 138 stocks over the last week.</li>
<li>A-H premium decline of 1.7ppt last week was led by the health care consumer discretionary, and information technology sectors. </li>
<li>We highlight stocks at 52w high A-H premium: Flat Glass, Shandong Chenming Paper, CCC , Tianjin Capital, QHD Port, Beijing North Star, Shenzhen HepaLink.</li>
</ul>


We analyse the changes of A/H premium on 138 stocks over the last week.
A-H premium decline of 1.7ppt last week was led by the health care consumer discretionary, and information technology sectors. 
We highlight stocks at 52w high A-H premium: Flat Glass, Shandong Chenming Paper, CCC , Tianjin Capital, QHD Port, Beijing North Star, Shenzhen HepaLink.


A-H Premium Weekly: Real Estate at 52 Week High

<ul>
<li>We analyse the changes of A/H premium on 136 stocks over the last week.</li>
<li>Utilities and consumer staples sectors let the increase of A-H premium while communication services, consumer discretionary and industries led the decrease.</li>
<li>We highlight the following A-H stocks: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink.</li>
</ul>


We analyse the changes of A/H premium on 136 stocks over the last week.
Utilities and consumer staples sectors let the increase of A-H premium while communication services, consumer discretionary and industries led the decrease.
We highlight the following A-H stocks: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink.


A-H Premium Weekly: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink

China

Shenzhen Hepalink Pharmaceutical Group Co., Ltd researches, produces and sells heparin pharmaceuticals products. The Company's products include heparin sodium active pharmaceutical ingredient.

Shenzhen HepaLink Pharmaceutical (H) (9989 HK)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shenzhen HepaLink Pharmaceutical (H) (9989 HK)

A-H Premium Weekly: Zhejiang Shibao, PICC, CRRC

We highlight week-on-week A-H premium changes in stocks including Zhejiang Shibao, PICC, CRRC, Shandong Xinhua, and Shenwan Hongyuan.

Ke Yan, CFA, FRM

A-H Premium Weekly: Remegen, CNOOC, COSCO Shipping

We highlight A-H premium changes for stocks including Remegen, CNOOC, COSCO Shipping, Cansino, Nanjing Panda, Shenzhen Hepalink, SH Fudan, SH...

Ke Yan, CFA, FRM

A-H Premium Weekly: Healthcare Led Premium Decline

A-H premium declined by 3.0ppt last week, led by consumer staple, consumer discretionary and heathcare. We highlight names including Shenzhen...

Ke Yan, CFA, FRM

A-H Premium Weekly: Real Estate at 52 Week High

We highlight real estate sector at 52 eek high and stocks at 52w high A-H premium: Flat Glass, Shandong Chenming Paper, CCC , Tianjin Capital, QHD...

Ke Yan, CFA, FRM

A-H Premium Weekly: Shanghai Pharma, China Eastern Air, Huaneng Power, Shenzhen Hepalink

We highlight utilities, consumer staple, comm servcies, and consumer discretionary sector and the following A-H stocks: Shanghai Pharma, China...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)